SMMT

Summit Therapeutics Inc. Common Stock

SMMT · Salud · Next earnings: 19 Oct 2026 · Time not confirmed · Q3 2026

Relevance 22/100 · Minor

1-year price history

Source: Yahoo Finance

The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.

Company

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Sector Healthcare · Biotechnology
Website https://www.smmttx.com

What the market expects

ConsensusPrior-year EPS

EPS-0.21—

Revenue54,140—

12 analysts

How expectations have moved

Expectations: Neutral

Expectativas neutrales: cotiza un 41% por debajo de su máximo de 52 semanas.

Stock, 90 days: +8.8%

Prior behaviour

Average absolute move: 2.5%
Largest move: 4.5%
releases with a move larger than 5%: 0%
beat the EPS consensus in: 1 of the last 4

Quarter Date 1-session move Surprise EPS

Jun 2026 23 Jul 2026 +1.6% -7.7%

Mar 2026 30 Apr 2026 +3.0% +27.3%

Dec 2025 23 Feb 2026 +0.9% -31.8%

Sep 2025 20 Oct 2025 -4.5% -121.4%

Historical moves describe typical magnitude, not a future direction.

Expected move

±17.1% (options)

“±X%” is the typical move size, not a forecast of direction.

Stock situation

Price: 17.27
30 days: -1.9%
90 days: +8.8%
Distance to 52-week high: -40.9%
Market cap: 13,777,135,600

Metrics to watch

El trimestre anterior se quedó un 8% por debajo del consenso de BPA.
Ventas del fármaco o producto principal
Guidance de ingresos anual
Avances de pipeline / ensayos clínicos mencionados
Margen operativo
BPA e ingresos frente al consenso (sorpresa)
Cambio en el guidance respecto al trimestre anterior
Reacción del mercado frente al movimiento histórico y al implícito

Relevance breakdown

market_cap: 5.8
analyst_coverage: 4.8
estimate_revisions: 0.3
recent_price_move: 0.8
historical_earnings_vol: 3.8
sector_importance: 4.0
recent_news_coverage: 0.0

Disclaimer

Radar Acciones provides information and analysis tools, not personalised investment advice. Consensus and expectations data describe the setup around an event with objective figures; they must never be read as a forecast of direction or price.